5月7日，诺和诺德发布2025年第一季度业绩。财报显示，第一季度销售额780.9亿丹麦克朗，预估787亿丹麦克朗；第一季度EBIT387.9亿丹麦克朗，预估371.2亿丹麦克朗；第一季度净利润290.3亿丹麦克朗，预估279.1亿丹麦克朗；第一季度税前利润370.3亿丹麦克朗，预估352.6亿丹麦克朗。
第一季度减肥药Wegovy销售额173.6亿丹麦克朗，预估189.8亿丹麦克朗；第一季度Ozempic销售额327.2亿丹麦克朗，预估323.2亿丹麦克朗。
就2025年的展望而言，目前预计销售额增长率（按固定汇率计算）为13-21%，市场预估增长18.6%，此前预估增长16%-24%；营业利润增长率（按固定汇率计算）为16-24%，市场预估增长22.4%，此前预计增长19%-27%。
以丹麦克朗计算的销售额和营业利润增长率预计分别比固定汇率低3个百分点和5个百分点。更新后的销售预期反映了美国品牌GLP-1药物的渗透率低于预期，这主要受到复合GLP-1的影响。
财报发布后，诺和诺德美股夜盘一度跌超4%，现涨近5%；诺和诺德CEO：2025年将在“更多国家”推出减肥药Wegovy。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
